| NOBEL Pharma Schweiz AG - Ryaltris 25 μg / 600 μg, Nasenspray, Suspension | | 69672 | | 01 | | Ryaltris 25 μg / 600 μg | | Nasenspray, Suspension | | R01AD59 | | Mometasone, Combinations | | 23.06.2025 | | |
| | Composition | | mometasoni furoas 0.25 mg ut mometasoni furoas monohydricus olopatadinum 6 mg ut olopatadini hydrochloridum, cellulosum microcristallinum et carmellosum natricum, dinatrii phosphas heptahydricus, carmellosum natricum, natrii chloridum, benzalkonii chloridum 0.20 mg, dinatrii edetas, polysorbatum 80, acidum hydrochloridum concentratum, natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 1 g corresp. mometasoni furoas 25 µg et olopatadinum 600 µg pro dosi. | | Packungsbestandteile | | Nasal spray | | | | | | Active Agent | Dose |
|---|
| Mometasoni Furoas | 0.25 mg/g |
| | | | Inactive agents | Dose |
|---|
| Acidum Hydrochloridum Concentratum | | | Benzalkonium Chloride | 0.2 mg/g | | Carmellose Sodium | | | Cellulosum Microcristallinum | | | Dinatrii Edetas | | | Disodium Phosphate Heptahydrate | | | Sodium Chloride | | | Sodium Hydroxide | | | Polysorbatum 80 | |
|
| |
|
